[BLUE] bluebird bio, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 64.65 Change: 2.15 (3.44%)
Ext. hours: Change: 0 (0%)

chart BLUE

Refresh chart

Strongest Trends Summary For BLUE

BLUE is in the medium-term up 23% above S&P in 3 months. In the long-term down -24% below S&P in 1 year and up 144% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-7.22 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0.14% Sales Growth - Q/Q-0.66% P/E-15.06
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.78% ROE-13.25% ROI
Current Ratio8.11 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-294.47% Net Profit Margin-247.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.46 M Cash From Investing Activities-192.98 M Cash From Operating Activities-24.16 M Gross Profit
Net Profit-24.79 M Operating Profit-24.93 M Total Assets533.82 M Total Current Assets340.84 M
Total Current Liabilities42.01 M Total Debt Total Liabilities59.32 M Total Revenue6.34 M
Technical Data
High 52 week233.05 Low 52 week91.25 Last close149.91 Last change14.16%
RSI64.09 Average true range5.8 Beta1.74 Volume513.89 K
Simple moving average 20 days12.23% Simple moving average 50 days25.91% Simple moving average 200 days4.02%
Performance Data
Performance Week9.4% Performance Month22.09% Performance Quart28.83% Performance Half-7.23%
Performance Year-24.63% Performance Year-to-date51.12% Volatility daily3.75% Volatility weekly8.38%
Volatility monthly17.18% Volatility yearly59.51% Relative Volume135.56% Average Volume682.46 K
New High New Low

News

2019-03-25 08:24:04 | Massachusetts concern details plan to hire new workers in Durham

2019-03-23 09:30:01 | Why Is Bluebird BLUE Up 15.3% Since Last Earnings Report?

2019-03-22 08:00:00 | bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina

2019-03-12 10:30:05 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-03-12 10:07:02 | Celgene CELG Submits Application for MS Drug in Europe

2019-03-11 02:28:17 | Here's Why bluebird bio Gained 16.3% in February

2019-03-08 08:00:00 | bluebird bio to Present at Investor Conferences in March

2019-03-07 12:32:45 | What Are Analysts Saying About bluebird bio, Inc.’s NASDAQ:BLUE Earnings Outlook?

2019-03-05 08:04:11 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-02-26 16:21:00 | With a Stocked War Chest, bluebird bio Presses On

2019-02-26 11:15:04 | Biotech ETFs Jump on Roche-Spark Deal

2019-02-23 20:10:00 | Better Buy: bluebird bio vs. Gilead Sciences

2019-02-22 14:46:07 | bluebird BLUE Q4 Earnings Beat Estimates, Revenues Up Y/Y

2019-02-21 19:15:12 | Bluebird Bio BLUE Reports Q4 Loss, Tops Revenue Estimates

2019-02-21 18:17:36 | Bluebird: 4Q Earnings Snapshot

2019-02-21 16:05:00 | bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

2019-02-14 07:55:00 | Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext — New Horizons, Emerging Trends, and Upcoming Developments

2019-02-13 10:31:03 | Earnings Preview: Bluebird Bio BLUE Q4 Earnings Expected to Decline

2019-02-12 09:11:02 | AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

2019-02-11 06:30:00 | bluebird bio Appoints Chip Baird as Chief Financial Officer

2019-02-08 08:03:15 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-02-06 13:52:06 | Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

2019-02-01 14:11:36 | German firm that serves gene therapy biotechs opens Cambridge HQ

2019-01-31 11:46:04 | Celgene CELG Q4 Earnings Beat Estimates, Revenues Up Y/Y

2019-01-31 07:55:00 | Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics

2019-01-28 11:52:03 | Did bluebird bio, Inc. NASDAQ:BLUE Insiders Sell Shares?

2019-01-24 10:51:03 | The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

2019-01-24 10:12:00 | Where Will bluebird bio Be in 5 Years?

2019-01-23 10:48:03 | 5 Best Biotech Bets Likely to Outperform Estimates in Q4

2019-01-22 11:50:00 | Here's Why CRISPR Therapeutics Stock Fell Today

2019-01-22 08:06:14 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-01-21 14:00:00 | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-01-15 08:03:53 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-01-12 09:41:00 | Here's What Pushed bluebird bio Stock Down 44.3% in 2018

2019-01-12 07:31:00 | 3 Biotech Stocks to Watch in 2019

2019-01-11 09:56:00 | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation Against bluebird bio, Inc. BLUE

2019-01-11 06:55:00 | Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical

2019-01-10 08:01:00 | Three tech, three biotech companies that are top takeover targets in 2019

2019-01-09 08:02:03 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-01-08 19:33:16 | Biotech Proposes Paying for Pricey Drugs by Installment

2019-01-08 17:31:10 | Celgene CELG Provides Guidance for 2019, Updates Pipeline

2019-01-07 08:00:00 | bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

2019-01-04 12:16:00 | Here's Why bluebird bio Shares Got Knocked Down 19.3% in December

2019-01-04 12:05:02 | How Celgene Is Positioned Now

2019-01-04 10:13:37 | Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout

2019-01-04 10:01:03 | Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

2019-01-03 10:30:00 | ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-01-03 08:00:00 | bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference

2019-01-02 16:00:02 | How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

2019-01-02 14:30:02 | A Financial Overview of Sangamo Therapeutics in December 2018